

Kicking off 2020 with Continued Transparency

We hope that the Holidays have been a joyful time for all and look forward to growing scalp cooling around the world in 2020.

With this monthly newsletter we aim to acknowledge the latest operational news as a means of increasing transparency to the market, so this month we are featuring a few of the most common Shareholder Questions.

Shareholder Question

How many patients can use DigniCap each day at a clinic?

The number of treatments varies greatly based on how long the facility has been offering DigniCap and awareness of scalp cooling among clinicians and patients. Once a facility introduces DigniCap the number of daily treatments typically builds over the first 4 to 6 months. Our busiest clinics use each DigniCap device they have for 2 or 3 treatments each weekday.

Which markets are you working on for regulatory approval?

The demand for DigniCap around the globe has increased tremendously in recent months and we have seen increased awareness and interest especially in Asia and South America. We have added resources to our Global Sales team to respond to this trend and have also implemented a strategic plan to guide global sales efforts in the most effective and efficient manner. We will announce new distributorships and sales in new regions as they occur.

Extraordinary Shareholder Meeting Scheduled

Dignitana has announced an Extraordinary General Meeting on 10 February 2020 at the company headquarters in Lund. [Details are posted here.](#)

Year End Report will be published February 25, 2020

Dignitana's 2019 Year End Report will be published on 25 February 2020. [Financial reports are posted here.](#)


Life Science Day Presentation

The latest IR presentation of Dignitana was given by CEO William Cronin at the Redeye Life Science Day November 19, 2019. The presentation can be [viewed here.](#)

Dignitana Exhibitions Scheduled

Kicking off 2020, Dignitana and Middle East distributor Tesla Medical Solutions will exhibit at Arab Health, January 27-30 in Dubai, UAE.

Dignitana is also a sponsor and exhibitor of the Atlantic Health System San Antonio Breast Cancer Symposium review in Summit, New Jersey on January 26, 2020.



Dr. Angad Deengar at San Antonio Breast Cancer Symposium

DigniCap study with anthracycline regimens presented at San Antonio Conference

In December 2019, Dignitana participated in the prestigious San Antonio Breast Cancer Symposium in San Antonio, Texas, USA.

Dr. Angad Deengar of Norwalk Hospital in Connecticut presented a poster highlighting impressive results of a retrospective study of DigniCap use at their facility tracking success by chemotherapy regimen.

Chemotherapy Regimen	Total patients	Successful Outcome	Percent Successful
Taxane-based only	54	43	80 %
Combination Anthracycline and Taxane	25	15	60 %
Anthracycline only	4	3	75 %
Non-Anthracycline or Taxane-based	7	7	100 %

For more information on the study [click here.](#)

DigniCap Availability

The DigniCap Scalp Cooling System is now available in 38 countries and in 30 states in the United States.

New locations since the last newsletter include:

- Augusta Oncology - Downtown, Augusta Georgia US
- Augusta Oncology - Wheeler, Augusta, Georgia US
- Augusta Oncology, Aiken, South Carolina, US
- Waverly Hematology Oncology, Cary, North Carolina, US

Dignitana AB, Traktorgränden 3, SE-226 60 Lund Sweden

Per MAR guidelines, company announcements are posted at www.dignitana.se and distributed to Nasdaq First North Growth Market, Nordic News Agencies, EU Transparency, and financial websites [Subscribe here](#) to receive this newsletter by email or email investorrelations@dignitana.com